The Food and Drug Administration (FDA) has approved PARI’s eRapid Nebulizer System (eRapid), the first electronic nebulizer to deliver Pulmozyme (dornase alfa [recombinant human DNase]; Genentech) for the treatment of cystic fibrosis.
Use with eRapid reduces the usual Pulmozyme treatment time from 6–8 minutes to 2–3 minutes. It is compact, portable, and is supplied with two complete nebulizer handsets to alternate or use while traveling. Also, the eBase Controller provides the user with feedback on battery life, proper assembly, medication loading, and end of treatment. A clinical study showed both adults and children strongly preferred the use of eRapid (20:1 and 10:1, respectively) vs. conventional nebulizers.
Pulmozyme is indicated for the management of cystic fibrosis in conjunction with standard therapies to improve pulmonary function.
eRapid is available by prescription through select specialty pharmacies.
For more information call (800) FAST-NEB or visit PARI.com.